Generic Drugs Medicine Pharma Companies Pharma Production 
Pharmaceutical Technology
AUGUST 12, 2022
In principle, the deal could create new opportunities for British pharma companies – not least the chance to work under a more supportive regulatory framework. Among the negative effects that have been reported are supply chain disruptions, skills shortages, issues around market authorisation, and added costs for pharma CMOs.
Pharmaceutical Technology
MARCH 22, 2023
Despite having large biopharmaceutical companies on home ground, the UK and France experienced major shortages and supply chain issues. Only 25% of API production for generic drugs took place in Europe in 2020, according to a November 2022 Medicines for Europe report. For innovative medicines, this share was 77%.
Expert insights. Personalized for you.
290 
Let's personalize your content